• Home
  • Search Results

Research Studies

UNC-Chapel Hill Division of Hematology

30 studies match your search
Coming Soon

Study of AUTX-007 for Leukemia

The purpose of the study is to find out is AUTX-007 an investigational drug, can help treat or cure cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Coming Soon

APVO436-5201: APVO436 Phase 1b/2 Study in Patients with Newly Diagnosed acute myeloid leukemia (AML).

We are looking for a dose of the APVO436 in combination with venetoclax and azacitidine that can be administered safely to participants who have been diagnosed with AML.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Open

Understanding Sickle Cell Trait

Do you have sickle cell trait or wonder if you might? Join our study to learn more about how having sickle cell trait could impact your health. The study uses simple lab tests, and participants receive compensation.

Age & Gender
  • 18 years ~ 65 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Healthy Volunteer or General Population
  • Minority Health
Open

Advanced Cancer Decisions Study

Do you have an advanced cancer? Are you 60+ years old? If so, you may be able to take part in a study to understand how patients and doctors communicate when choosing treatments. Compensation provided.

Age & Gender
  • 60 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 15 more)
Visit Location
Open

Neutrophil Blood Cell Count Study

Are you Black/African American or have Middle Eastern ancestry? Are you not taking any medicines that could change your blood count? If so, you might be able to join a study to find out the normal levels of a type of blood cell called neutrophils. Compensation provided.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Healthy Volunteer or General Population
  • UNC or UNC Health employees
Open

A Phase III Multicenter Randomized Trial to Study HQP1351 in Patients with Chronic Myeloid Leukemia (CML)

Have you been diagnosed with Chronic Myeloid Leukemia, have a T315I mutation, and previously treated with at least two tyrosine kinase inhibitors (TKIs)? You might be able to participate in this study.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)

Randomized Study of Sonrotoclax + Zanubrutinib vs Venetoclax + Obinutuzumab in Pts w/ CLL

The purpose of this research study is to compare the effectiveness of two combinations of anticancer study drugs in treating your Chronic Lymphocytic Leukemia (CLL). The first combination is sonrotoclax (also known as BGB-11417) and zanubrutinib, while the second combination is venetoclax and obinutuzumab. The aim is to determine which combination of study drugs is more effective in controlling your specific type of cancer,

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Leukemia, Lymphoma)

A Comparator Study of a Tasso device to traditional venous blood sampling methods for CBC in patients with leukemia, lymphoma, or other blood cell disorders

This study will evaluate the feasibility of using capillary blood samples collected with the Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or other blood cell disorders.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Leukemia, Lymphoma)
Open

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma [A052101]

Are you over 60 and were recently diagnosed with mantle cell lymphoma? You may be able to participate in a research study to determine whether patients who reach complete disease remission after treatment with rituximab and zanubrutinib, will remain longer in remission with or without continuous zanubrutinib treatment.

Age & Gender
  • 60 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

An Acute Leukemia Study

Do you have Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia? Are you looking for other treatment options? We are doing a study to find out whether treatment with the study drug (Bexmarilimab) along with standard treatment can help your cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research